ArticleEndocrine connections2025
Hypoparathyroidism induced by immune checkpoint inhibitors: a review of literature reports and real-world pharmacovigilance data.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Endocrine adverse events of immune checkpoint inhibitors].Magyar onkologia · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to comprehensively assess the characteristics of immune checkpoint inhibitor (ICI)-induced hypoparathyroidism (HP) by analyzing published case reports and adverse event data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: We identified case reports of HP during ICI treatment through a systematic literature search and extracted clinical data. FAERS data (Q2 2011-Q3 2024) were analyzed for cases where ICIs were the primary suspected cause of HP. Disproportionality and Bayesian analyses were used to evaluate associations between ICI classes and HP. Results: Nine ICI-related HP cases were documented in the literature. Predominant manifestations included neuromuscular symptoms (e.g., weakness, paresthesia). Laboratory findings consistently revealed hypocalcemia and low parathyroid hormone (PTH) levels. Four cases exhibited prolonged QT intervals, and calcium-sensing receptor (CaSR) autoantibodies were detected in four patients. Pharmacovigilance analysis showed the strongest signal for CTLA-4/PD-1 inhibitor combination therapy (ROR (95% CI): 6.04 (2.26-16.13); PRR (χ 2): 6.04 (16.71); EBGM (EBGM05): 6.01 (2.64); IC (IC025): 2.59 (1.29)). Conclusion: ICI-induced HP is a rare endocrine toxicity requiring heightened clinical vigilance. Regular monitoring of serum calcium levels is essential, with PTH measurements recommended in the presence of hypocalcemia to facilitate early diagnosis and appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.